Cavitary pulmonary disease in a patient treated with natalizumab

Presse Medicale

Volumn 43, Issue 9, 2014, Pages 1009-1012

  de Masson, Adèle ^a   Maillart, Elisabeth ^a   Veziris, Nicolas ^a,b   Meyssonnier, Vanina ^a   Papeix, Caroline ^a   Caumes, Eric ^a,b  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b SORBONNE UNIVERSITÉ   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; BETA1A INTERFERON; CLARITHROMYCIN; ETHAMBUTOL; FINGOLIMOD; METHYLPREDNISOLONE; NATALIZUMAB; RIFABUTIN; ANTIINFECTIVE AGENT; MONOCLONAL ANTIBODY; TUBERCULOSTATIC AGENT;

ADULT; ARTHRALGIA; ASTHENIA; ATYPICAL MYCOBACTERIOSIS; BACTERIAL PNEUMONIA; BACTERIUM IDENTIFICATION; CASE REPORT; CLINICAL EFFECTIVENESS; CLINICAL FEATURE; DIAGNOSTIC IMAGING; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; IMAGE ANALYSIS; LETTER; LUNG DISEASE; MEDICAL HISTORY; MULTIPLE SCLEROSIS; MYCOBACTERIUM INTRACELLULARE; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT ASSESSMENT; RELAPSE; SCORING SYSTEM; THORAX RADIOGRAPHY; TREATMENT DURATION; MICROBIOLOGY; MYCOBACTERIUM INTRACELLULARE AVIUM;

ADULT; ANTI-BACTERIAL AGENTS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTITUBERCULAR AGENTS; CLARITHROMYCIN; ETHAMBUTOL; FEMALE; HUMANS; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; MYCOBACTERIUM AVIUM COMPLEX; MYCOBACTERIUM AVIUM-INTRACELLULARE INFECTION; PNEUMONIA, BACTERIAL;

EID: 84908295305     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lpm.2013.12.012     Document Type: Letter

References (22)

1. Von Andrian U.H., Engelhardt B. Alpha4 integrins as therapeutic targets in autoimmune disease. N Engl J Med 2003, 348:68-72.
2. Yousry T.A., Major E.O., Ryschkewitsch C., Fahle G., Fischer S., Hou J., et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med 2006, 354:924-933.
3. Kurtzke J.F. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983, 33:1444-1452.
4. Rudick R.A., Kappos L. Measuring disability in relapsing-remitting MS. Neurology 2010, 75:296-297.
5. Rudick R.A., Lee J.C., Cutter G.R., Miller D.M., Bourdette D., Weinstock-Guttman B., et al. Disability progression in a clinical trial of relapsing-remitting multiple sclerosis: eight-year follow-up. Arch Neurol 2010, 67:1329-1335.
6. Griffith D.E., Aksamit T., Brown-Elliott B.A., Catanzaro A., Daley C., Gordin F., et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007, 175:367-416.
7. Winthrop K.L., McNelley E., Kendall B., Marshall-Olson A., Morris C., Cassidy M., et al. Pulmonary nontuberculous mycobacterial disease prevalence and clinical features: an emerging public health disease. Am J Respir Crit Care Med 2010, 182:977-982.
8. Reich J.M., Johnson R.E. Mycobacterium avium complex pulmonary disease presenting as an isolated lingular or middle lobe pattern. The Lady Windermere syndrome. Chest 1992, 101:1605-1609.
9. Le Page E., Leray E., Edan G., French Mitoxantrone Safety Group Long-term safety profile of mitoxantrone in a French cohort of 802 multiple sclerosis patients: a 5-year prospective study. Mult Scler Houndmills Basingstoke Engl 2011, 17:867-875.
10. Langer-Gould A., Atlas S.W., Green A.J., Bollen A.W., Pelletier D. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 2005, 353:375-381.
11. Kleinschmidt-DeMasters B.K., Tyler K.L. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med 2005, 353:369-374.
12. Van Assche G., Van Ranst M., Sciot R., Dubois B., Vermeire S., Noman M., et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med 2005, 353:362-368.
13. Miller D.H., Khan O.A., Sheremata W.A., Blumhardt L.D., Rice G.P.A., Libonati M.A., et al. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2003, 348:1-23.
14. Polman C.H., O'Connor P.W., Havrdova E., Hutchinson M., Kappos L., Miller D.H., et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006, 354:899-910.
15. Rudick R.A., Stuart W.H., Calabresi P.A., Confavreux C., Galetta S.L., Radue E.W., et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 2006, 354:911-923.
16. Dahdaleh D., Altmann D.M., Malik O., Nicholas R.S. Breathlessness, night sweats, and weight loss on natalizumab. Lancet 2012, 380:726-727.
17. Hradilek P., Zeman D., Tudik I., Zapletalova O., Ulmann V. Asymptomatic lung disease caused by Mycobacterium kansasii as an opportunistic infection in a patient treated with natalizumab for relapsing-remitting multiple sclerosis. Mult Scler 2013, [Epub ahead of print] doi:10.1177/1352458513501572.
18. Hamdi H., Mariette X., Godot V., Weldingh K., Hamid A.M., Prejean M.V., et al. Inhibition of anti-tuberculosis T-lymphocyte function with tumour necrosis factor antagonists. Arthritis Res Ther 2006, 8:R114.
19. Browne S.K., Burbelo P.D., Chetchotisakd P., Suputtamongkol Y., Kiertiburanakul S., Shaw P.A., et al. Adult-onset immunodeficiency in Thailand and Taiwan. N Engl J Med 2012, 367:725-734.
20. Al-Muhsen S., Casanova J.L. The genetic heterogeneity of mendelian susceptibility to mycobacterial diseases. J Allergy Clin Immunol 2008, 122:1043-1051.
21. Hsu A.P., Johnson K.D., Falcone E.L., Sanalkumar R., Sanchez L., Hickstein D.D., et al. GATA2 haploinsufficiency caused by mutations in a conserved intronic element leads to MonoMAC syndrome. Blood 2013, 121:3830-3837. [S1-S7].
22. Spinner M.A., Sanchez L.A., Hsu A.P., Shaw P.A., Zerbe C.S., Calvo K.R., et al. GATA2 deficiency: a protean disorder of hematopoiesis, lymphatics and immunity. Blood 2014, 123:809-821.